英国剑桥的一家社区大眼诊所的患者报告结果和经验措施 (POEM):一项观察性研究

Emily Charlesworth1, Jasleen Kaur Jolly2,3, Sarah Farrell4

  • 1Faculty of Health Education Medicine and Social Care, Vision and Eye Research Institute, Anglia Ruskin University, Cambridge, UK emily.charlesworth@aru.ac.uk.

BMJ open
|January 23, 2024
PubMed
概括

患者报告说,他们对英国社区玻璃眼科诊所的积极经验,感到安全和得到了良好的照顾. 年轻的患者和那些怀疑患有青光眼的人可能需要更多的支持来理解他们的诊断.

相关概念视频

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
573
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
500
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
452